002370 亚太药业
已收盘 12-15 15:00:00
资讯
新帖
简况
亚太药业（002370）披露拟变更会计师事务所及多项制度修订公告，12月8日股价上涨2.31%
证券之星 · 12-08
亚太药业（002370）披露拟变更会计师事务所及多项制度修订公告，12月8日股价上涨2.31%
亚太药业：优化产品结构拓展海外市场
证券之星 · 12-05
亚太药业：优化产品结构拓展海外市场
股市必读：亚太药业（002370）11月18日收盘跌6.19%，主力净流出2501.85万元
证券之星 · 11-19
股市必读：亚太药业（002370）11月18日收盘跌6.19%，主力净流出2501.85万元
一款仿制药未过评，新东家能拯救亚太药业吗？
视频滚动新闻 · 11-14
一款仿制药未过评，新东家能拯救亚太药业吗？
亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价申请不予批准
智通财经 · 11-06
亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价申请不予批准
11月4日亚太药业（002370）龙虎榜数据：机构净买入8831.23万元
证券之星 · 11-04
11月4日亚太药业（002370）龙虎榜数据：机构净买入8831.23万元
异动快报：亚太药业（002370）10月31日11点2分触及涨停板
证券之星 · 10-31
异动快报：亚太药业（002370）10月31日11点2分触及涨停板
亚太药业（002370）2025年三季报简析：净利润同比增长2909.49%，三费占比上升明显
证券之星 · 10-30
亚太药业（002370）2025年三季报简析：净利润同比增长2909.49%，三费占比上升明显
亚太药业(002370)9月30日股东户数9.15万户，较上期增加66%
证券之星 · 10-28
亚太药业(002370)9月30日股东户数9.15万户，较上期增加66%
股市必读：亚太药业（002370）登10月17日交易所龙虎榜
证券之星 · 10-20
股市必读：亚太药业（002370）登10月17日交易所龙虎榜
10月17日亚太药业（002370）龙虎榜数据：机构净买入5779.76万元
证券之星 · 10-17
10月17日亚太药业（002370）龙虎榜数据：机构净买入5779.76万元
10月15日亚太药业（002370）龙虎榜数据：机构净卖出1015.7万元（3日）
证券之星 · 10-15
10月15日亚太药业（002370）龙虎榜数据：机构净卖出1015.7万元（3日）
亚太药业最新公告：拟向特定对象发行股票 募资不超7亿元用于新药研发
证券之星 · 10-13
亚太药业最新公告：拟向特定对象发行股票 募资不超7亿元用于新药研发
亚太药业计划通过定向增发募资不超过7亿元用于研发项目
美股速递 · 10-13
亚太药业计划通过定向增发募资不超过7亿元用于研发项目
9亿并购埋雷 六年连亏27亿 亚太药业再度易主求生
新浪证券 · 10-11
9亿并购埋雷 六年连亏27亿 亚太药业再度易主求生
多家A股公司控制权拟变更！301075，002370，300692，停牌！300948，复牌！
e公司 · 09-28
多家A股公司控制权拟变更！301075，002370，300692，停牌！300948，复牌！
亚太药业最新公告：筹划公司控制权变更事项 股票停牌
证券之星 · 09-28
亚太药业最新公告：筹划公司控制权变更事项 股票停牌
9月5日亚太药业（002370）龙虎榜数据：机构净卖出5094.49万元
证券之星 · 09-05
9月5日亚太药业（002370）龙虎榜数据：机构净卖出5094.49万元
图解亚太药业中报：第二季度单季净利润同比增长1233.32%
证券之星 · 08-29
图解亚太药业中报：第二季度单季净利润同比增长1233.32%
亚太药业(002370)6月30日股东户数5.51万户，较上期减少9.36%
证券之星 · 08-29
亚太药业(002370)6月30日股东户数5.51万户，较上期减少9.36%
公司概况
公司名称：
浙江亚太药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-03-16
主营业务：
浙江亚太药业股份有限公司的主营业务是化学制剂的研发、生产和销售。公司的主要产品是抗生素类药品和非抗生素类药品。
发行价格：
16.00
{"stockData":{"symbol":"002370","market":"SZ","secType":"STK","nameCN":"亚太药业","latestPrice":7.15,"timestamp":1765782195000,"preClose":7.24,"halted":0,"volume":25892326,"delay":0,"changeRate":-0.0124,"floatShares":746000000,"shares":746000000,"eps":0.181,"marketStatus":"已收盘","change":-0.09,"latestTime":"12-15 15:00:00","open":7.23,"high":7.29,"low":7.13,"amount":186000000,"amplitude":0.0221,"askPrice":7.16,"askSize":4744,"bidPrice":7.15,"bidSize":2693,"shortable":0,"etf":0,"ttmEps":0.181,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"adjPreClose":7.24,"symbolType":"stock","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":7.96,"lowLimit":6.52,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":745667530,"isCdr":false,"pbRate":4.82,"roa":"--","peRate":39.502762,"roe":"9.21%","epsLYR":0.05,"committee":0.181836,"marketValue":5332000000,"turnoverRate":0.0347,"status":1,"floatMarketCap":5332000000},"requestUrl":"/m/hq/s/002370/wiki","defaultTab":"wiki","newsList":[{"id":"2589305359","title":"亚太药业（002370）披露拟变更会计师事务所及多项制度修订公告，12月8日股价上涨2.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589305359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589305359?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:19","pubTimestamp":1765203578,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，亚太药业报收于7.53元，较前一交易日上涨2.31%，最新总市值为56.15亿元。该股当日开盘7.4元，最高7.67元，最低7.4元，成交额达4.03亿元，换手率为7.19%。近日，浙江亚太药业股份有限公司发布公告称，公司将于2025年12月24日召开2025年第三次临时股东大会，会议由董事会召集，现场会议时间为当日14:00，网络投票时间为9:15至15:00。股权登记日为2025年12月18日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800034891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2589851238","title":"亚太药业：优化产品结构拓展海外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2589851238","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589851238?lang=zh_cn&edition=full","pubTime":"2025-12-05 09:24","pubTimestamp":1764897856,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业12月04日在投资者关系平台上答复投资者关心的问题。公司目前正积极应对市场环境变化，通过优化产品结构，拓展营销渠道，探索新营销模式和海外市场的开发，加大费用管控，降本增效，努力提升盈利能力，以期实现公司的持续、稳定、健康发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500005733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2584895952","title":"股市必读：亚太药业（002370）11月18日收盘跌6.19%，主力净流出2501.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584895952","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584895952?lang=zh_cn&edition=full","pubTime":"2025-11-19 01:00","pubTimestamp":1763485254,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，亚太药业报收于8.34元，下跌6.19%，换手率15.01%，成交量111.91万手，成交额9.44亿元。交易信息汇总股价提醒11月18日亚太药业收盘报8.34元，跌6.19%，当日成交1.12亿元。前10个交易日资金流向情况：主力资金累计净流出3.82亿元，股价累计下跌7.86%；融资余额累计增加1.15亿元，融券余量累计增加0股。资金流向11月18日主力资金净流出5240.31万元；游资资金净流入543.98万元；散户资金净流入4696.33万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900000623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2583526335","title":"一款仿制药未过评，新东家能拯救亚太药业吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583526335","media":"视频滚动新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583526335?lang=zh_cn&edition=full","pubTime":"2025-11-14 13:06","pubTimestamp":1763096760,"startTime":"0","endTime":"0","summary":"亚太药业盐酸地尔硫䓬片一致性评价申请被国家药监局不予批准，虽称未过评不影响当期业绩，但隐忧不小。公司已连续六年扣非亏损超25亿元，2024年营收逼近退市警戒线，2025年前三季度扣非仍亏损。公司拟变更控股股东并定增7亿用于新药研发，但创新项目短期难有实质贡献，仍需稳住仿制药基本盘。近年来仿制药监管加码，BE试验成研发“拦路虎”，行业洗牌加速，集中度将进一步提升。(AI生成)\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-11-14/doc-infxiwew9294372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2581560210","title":"亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价申请不予批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2581560210","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581560210?lang=zh_cn&edition=full","pubTime":"2025-11-06 15:55","pubTimestamp":1762415705,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)公告，公司近日收到国家药品监督管理局下发的关于盐酸地尔硫䓬片一致性评价的申请不予批准的通知书。盐酸地尔硫䓬片适用于心绞痛和轻、中度高血压的治疗。据通知书内容，本次不予批准的原因是：本次申报BE研究不能支持生物等效性结论。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价申请不予批准","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2580861387","title":"11月4日亚太药业（002370）龙虎榜数据：机构净买入8831.23万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580861387","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580861387?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:32","pubTimestamp":1762248774,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年11月4日公布的交易公开信息显示，亚太药业因日换手率达到20%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2025年11月4日收盘，亚太药业报收于9.06元，上涨3.9%，换手率38.87%，成交量289.81万手，成交额25.92亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入8831.23万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400027816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2579484794","title":"异动快报：亚太药业（002370）10月31日11点2分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2579484794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579484794?lang=zh_cn&edition=full","pubTime":"2025-10-31 11:05","pubTimestamp":1761879925,"startTime":"0","endTime":"0","summary":"证券之星10月31日盘中消息，11点2分亚太药业触及涨停板。目前价格7.93，上涨9.99%。其所属行业化学制药目前上涨。领涨股为舒泰神。该股为幽门螺杆菌概念，医药，化学原料药概念热股，当日幽门螺杆菌概念概念上涨2.82%，医药概念上涨2.52%，化学原料药概念上涨2.47%。10月30日的资金流向数据方面，主力资金净流入1118.15万元，占总成交额1.41%，游资资金净流出872.06万元，占总成交额1.1%，散户资金净流出246.1万元，占总成交额0.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100019876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2579130261","title":"亚太药业（002370）2025年三季报简析：净利润同比增长2909.49%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2579130261","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579130261?lang=zh_cn&edition=full","pubTime":"2025-10-30 06:27","pubTimestamp":1761776830,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚太药业发布2025年三季报。截至本报告期末，公司营业总收入2.28亿元，同比下降25.59%，归母净利润9719.5万元，同比上升2909.49%。按单季度数据看，第三季度营业总收入7623.1万元，同比下降10.21%，第三季度归母净利润-798.15万元，同比上升10.67%。本报告期亚太药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达43.89%。去年的净利率为8.45%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000005603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2578398479","title":"亚太药业(002370)9月30日股东户数9.15万户，较上期增加66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578398479","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578398479?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:32","pubTimestamp":1761643977,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亚太药业披露，截至2025年9月30日公司股东户数为9.15万户，较6月30日增加3.64万户，增幅为66.0%。在化学制药行业个股中，亚太药业股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.38万户。从股价来看，2025年6月30日至2025年9月30日，亚太药业区间涨幅为49.21%，在此期间股东户数增加3.64万户，增幅为66.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800031760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2576077731","title":"股市必读：亚太药业（002370）登10月17日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2576077731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576077731?lang=zh_cn&edition=full","pubTime":"2025-10-20 01:34","pubTimestamp":1760895249,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，亚太药业报收于7.75元，上涨2.65%，换手率37.93%，成交量282.83万手，成交额21.96亿元。当日关注点来自交易信息汇总：10月17日主力资金净流入3792.3万元，游资资金净流出4575.54万元。来自龙虎榜上榜：亚太药业因日振幅值达15%及日换手率达20%于10月17日登龙虎榜，近5个交易日内第2次上榜。龙虎榜上榜沪深交易所2025年10月17日公布的交易公开信息显示，亚太药业因日振幅值达到15%的前5只证券，日换手率达到20%的前5只证券登上龙虎榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000000577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2576080947","title":"10月17日亚太药业（002370）龙虎榜数据：机构净买入5779.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576080947","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576080947?lang=zh_cn&edition=full","pubTime":"2025-10-17 17:13","pubTimestamp":1760692431,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年10月17日公布的交易公开信息显示，亚太药业因日振幅值达到15%的前5只证券，日换手率达到20%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2025年10月17日收盘，亚太药业报收于7.75元，上涨2.65%，换手率37.93%，成交量282.83万手，成交额21.96亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入5779.76万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700027109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2575020912","title":"10月15日亚太药业（002370）龙虎榜数据：机构净卖出1015.7万元（3日）","url":"https://stock-news.laohu8.com/highlight/detail?id=2575020912","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575020912?lang=zh_cn&edition=full","pubTime":"2025-10-15 17:13","pubTimestamp":1760519635,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年10月15日公布的交易公开信息显示，亚太药业因连续三个交易日内，涨幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年10月15日收盘，亚太药业报收于6.86元，上涨9.94%，已连续涨停2天，换手率1.25%，成交量9.31万手，成交额6384.12万元。从龙虎榜公布的三日买卖数据来看，机构合计净卖出1015.7万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500027273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2575024244","title":"亚太药业最新公告：拟向特定对象发行股票 募资不超7亿元用于新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2575024244","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575024244?lang=zh_cn&edition=full","pubTime":"2025-10-13 22:00","pubTimestamp":1760364036,"startTime":"0","endTime":"0","summary":"亚太药业(002370.SZ)公告称，公司计划向特定对象发行股票，发行数量不超过1.37亿股（含本数），占发行前总股本的18.37%，发行价格为5.11元/股。募集资金总额不超过7亿元，全部用于新药研发项目。发行对象为浙江星浩控股合伙企业（有限合伙），其将以现金方式认购。此次发行不会导致公司控制权发生变化，但会增加公司的总股本和净资产，短期内可能摊薄净资产收益率和每股收益。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300024707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"1121025116","title":"亚太药业计划通过定向增发募资不超过7亿元用于研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1121025116","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121025116?lang=zh_cn&edition=full","pubTime":"2025-10-13 21:05","pubTimestamp":1760360718,"startTime":"0","endTime":"0","summary":"亚太药业表示，公司计划通过非公开发行股票的方式募集资金不超过7亿元，所募集资金将用于公司研发项目的投入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2574434666","title":"9亿并购埋雷 六年连亏27亿 亚太药业再度易主求生","url":"https://stock-news.laohu8.com/highlight/detail?id=2574434666","media":"新浪证券","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574434666?lang=zh_cn&edition=full","pubTime":"2025-10-11 16:01","pubTimestamp":1760169660,"startTime":"0","endTime":"0","summary":"近日，亚太药业发布公告称，公司控股股东宁波富邦控股集团有限公司及其一致行动人、实际控制人宋汉平等正在筹划控制权变更事项。这已是亚太药业自2021年“富邦系”入主后的第二次控制权更迭尝试，背后是公司连续六年半扣非净利润为负、累计亏损超27亿元的残酷现实。 从9亿并购埋雷，到财务造假余波未平，再到连续六年扣非亏损，亚太药业的控制权更迭已不仅是股东层面的博弈，更是一场与时间赛跑的“保壳之战”。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-10-11/doc-inftpeup5014564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2570524849","title":"多家A股公司控制权拟变更！301075，002370，300692，停牌！300948，复牌！","url":"https://stock-news.laohu8.com/highlight/detail?id=2570524849","media":"e公司","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570524849?lang=zh_cn&edition=full","pubTime":"2025-09-28 18:03","pubTimestamp":1759053780,"startTime":"0","endTime":"0","summary":" 9月28日晚间，多瑞医药、亚太药业和中环环保等多家A股公司披露筹划控制权变更事项。冠中生态则披露控股股东拟变更为深蓝财鲸。 具体来看，多瑞医药公告，公司控股股东西藏嘉康时代科技发展有限公司、实际控制人邓勇正在筹划公司控制权变更相关事宜，可能导致公司控股股东、实际控制人发生变更。经申请，公司股票自2025年9月29日起停牌，预计停牌时间不超过2个交易日。公司股票及可转债9月29日复牌。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-09-28/doc-infrzyrp2719117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300692","399300","159982","300948","BK0132","002370","BK0218","301075","BK0135","BK0239","BK0150"],"gpt_icon":0},{"id":"2570848064","title":"亚太药业最新公告：筹划公司控制权变更事项 股票停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2570848064","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570848064?lang=zh_cn&edition=full","pubTime":"2025-09-28 15:59","pubTimestamp":1759046390,"startTime":"0","endTime":"0","summary":"亚太药业(002370.SZ)公告称，公司于9月26日收到控股股东宁波富邦控股集团有限公司及一致行动人上海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队及一致行动人宋凌杰的通知，其正在筹划公司控制权变更事项，具体交易方案、协议条款等尚需进一步论证和磋商，目前相关各方尚未签署正式交易协议。上述事项可能导致公司控股股东及实际控制人发生变更。公司股票自2025年9月29日（星期一）开市起停牌，预计停牌时间不超过2个交易日。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800003648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2565720556","title":"9月5日亚太药业（002370）龙虎榜数据：机构净卖出5094.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2565720556","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565720556?lang=zh_cn&edition=full","pubTime":"2025-09-05 17:31","pubTimestamp":1757064668,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年9月5日公布的交易公开信息显示，亚太药业因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年9月5日收盘，亚太药业报收于6.45元，下跌6.39%，换手率15.74%，成交量117.38万手，成交额7.57亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出5094.49万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500029168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2563878047","title":"图解亚太药业中报：第二季度单季净利润同比增长1233.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563878047","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563878047?lang=zh_cn&edition=full","pubTime":"2025-08-29 19:16","pubTimestamp":1756466208,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业2025年中报显示，公司主营收入1.52亿元，同比下降31.48%；归母净利润1.05亿元，同比上升1820.97%；扣非净利润-4886.22万元，同比下降524.31%；其中2025年第二季度，公司单季度主营收入8752.42万元，同比下降19.86%；单季度归母净利润1.13亿元，同比上升1233.32%；单季度扣非净利润-4129.84万元，同比下降635.46%；负债率9.14%，投资收益1.5亿元，财务费用3066.27万元，毛利率31.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900038231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2563126043","title":"亚太药业(002370)6月30日股东户数5.51万户，较上期减少9.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563126043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563126043?lang=zh_cn&edition=full","pubTime":"2025-08-29 17:32","pubTimestamp":1756459935,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亚太药业披露，截至2025年6月30日公司股东户数为5.51万户，较3月31日减少5691.0户，减幅为9.36%。在化学制药行业个股中，亚太药业股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.29万户。从股价来看，2025年3月31日至2025年6月30日，亚太药业区间涨幅为14.11%，在此期间股东户数减少5691.0户，减幅为9.36%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900033084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765814209167,"stockEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":-0.1938},{"period":"3month","weight":0.1734},{"period":"6month","weight":0.9255},{"period":"1year","weight":0.753},{"period":"ytd","weight":1.3738}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江亚太药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"91465人(较上一季度增加66.00%)","perCapita":"8152股","listingDate":"2010-03-16","address":"浙江省绍兴市柯桥区群贤路2003号1501室","registeredCapital":"74566万元","survey":" 浙江亚太药业股份有限公司的主营业务是化学制剂的研发、生产和销售。公司的主要产品是抗生素类药品和非抗生素类药品。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚太药业,002370,亚太药业股票,亚太药业股票老虎,亚太药业股票老虎国际,亚太药业行情,亚太药业股票行情,亚太药业股价,亚太药业股市,亚太药业股票价格,亚太药业股票交易,亚太药业股票购买,亚太药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}